Titlebook: Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Ronald T. Borchardt,Edward H. Kerns,James L. Steve Book 2006 Springer-Ve

健壯

Compass

John S. Walshebted to the national experts of COST Action E12 ‘Urban Forests and Trees’ and to the others who have contributed to the various chapters in this publication. Ultimately, 59 authors from 21 European countries feature in this book. The European Cooperation in the field of Scientific and Technical Res

FECK

Liang-Shang Gan,Frank W. Lee,Nelamangala Nagaraja,Ping Li,Jason Labutti,Wei Yin,Cindy Xia,Hua Yang,Vebted to the national experts of COST Action E12 ‘Urban Forests and Trees’ and to the others who have contributed to the various chapters in this publication. Ultimately, 59 authors from 21 European countries feature in this book. The European Cooperation in the field of Scientific and Technical Res

grudging

APRON

STALE

Lipid-based Systems, Drug Exposure and Lead Optimization,rious drugs including cyclosporine, saquinavir, ritonavir, dutasteride and amprenavir. Consequently, lipid-based systems are often considered when needing to increase drug exposure during pre-clinical drug development.

Keratectomy

Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure,ninterpretable study outcomes is highly inefficient, and based on poor data, a compound may be given an undeservedly low priority. Because exposure is such a critical factor for compound evaluation during lead optimization, the formulation of the compound can be a key component of the drug selection process.